596817-46-8 Usage
Uses
Used in Organic Chemistry Research:
[1-(6-CHLORO-PYRIDAZIN-3-YL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a research compound for exploring its chemical properties and potential applications in the field of organic chemistry. Its unique structure and functional groups make it an interesting subject for scientific investigation.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, [1-(6-CHLORO-PYRIDAZIN-3-YL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER may be used as a starting material or intermediate in the synthesis of various pharmaceutical compounds. Its chemical characteristics, such as the presence of the piperidine ring and the carbamic acid ester functional group, could potentially contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
[1-(6-CHLORO-PYRIDAZIN-3-YL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER can be used as a building block in the synthesis of more complex organic molecules. Its versatile structure allows for further chemical modifications, making it a valuable component in the creation of new compounds with potential applications in various industries, such as materials science, agrochemistry, and specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 596817-46-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,6,8,1 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 596817-46:
(8*5)+(7*9)+(6*6)+(5*8)+(4*1)+(3*7)+(2*4)+(1*6)=218
218 % 10 = 8
So 596817-46-8 is a valid CAS Registry Number.
596817-46-8Relevant articles and documents
COMPOUND AS GLS1 INHIBITOR
-
Paragraph 0080, (2020/05/07)
A compound as a GLS1 inhibitor as represented by formula (I) or a pharmaceutically acceptable salt thereof.
NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS
-
Page/Page column 187, (2008/06/13)
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
NEW COMPOUNDS
-
Page/Page column 33; 34, (2008/06/13)
The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.
